Buy reiterated for Sana stock after Phase 1 data supports unique …

Jan 8, 2025 · The adjustment follows Sana's recent report on its Phase 1 study of allogeneic hypoimmune (HIP) modified pancreatic islet cells aimed at treating type 1 diabetes (T1D) …

$7.00
OFF

Buy Reiterated For Sana Stock After Phase 1 Data Supports Unique …

2 weeks from now

BofA Securities analysts, led by Geoff Meacham, reiterated their Buy rating on Sana Biotechnology stock, maintaining a price target of $7.00. On the other hand, Citi increased its …

investing.com

$11
OFF

Buy Reiterated For Sana Stock After Phase 1 Data Supports Unique …

2 weeks from now

Jan 8, 2025 · On Tuesday, H.C. Wainwright analyst Emily Bodnar increased the price target for Sana Biotechnology (NASDAQ:SANA) shares to $11 from the previous $8, while maintaining a …

investing.com

$7.00
OFF

Sana Stock Soars On Positive T1D Study Results, BofA Maintains Buy

2 weeks from now

Jan 8, 2025 · BofA Securities analysts, led by Geoff Meacham, reiterated their Buy rating on Sana Biotechnology stock, maintaining a price target of $7.00. InvestingPro data reveals that analyst …

investing.com

$11
OFF

H.C. Wainwright Ups Sana Target After ‘best Case Scenario’ Data

2 weeks from now

Jan 8, 2025 · H.C. Wainwright raised the firm’s price target on Sana Biotechnology (SANA) to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for …

nasdaq.com

200%
OFF

Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows

2 weeks from now

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes spiking to 54 times the daily average. The surge followed …

msn.com

$11
OFF

Buy Reiterated For Sana Stock After Phase 1 Data Supports Unique …

2 weeks from now

Jan 8, 2025 · On Tuesday, H.C. Wainwright analyst Emily Bodnar increased the price target for Sana Biotechnology (NASDAQ:SANA) shares to $11 from the previous $8, while maintaining a …

investing.com

$7.00
OFF

Sana Biotechnology Inc Stock Price Today - Investing.com

2 weeks from now

Buy reiterated for Sana stock after Phase 1 data supports unique HIP cell platform. ... BofA Securities analysts reiterated a Buy rating and $7.00 price target on Sana Biotechnology …

investing.com

152%
OFF

SANA Stock Surges 152% In A Week On Upbeat Initial Diabetes …

2 weeks from now

6 days ago · Shares of Sana Biotechnology (SANA Quick Quote SANA - Free Report) skyrocketed 151.5% in the past week after the company announced positive initial results from …

zacks.com

FAQs about Buy reiterated for Sana stock after Phase 1 data supports unique … Coupon?

Should you buy Sana biotechnology (Sana) stock?

JMP Securities analyst Reni Benjamin has reiterated their bullish stance on SANA stock, giving a Buy rating on August 9. Reni Benjamin has given his Buy rating due to a combination of factors, including several upcoming updates on Sana Biotechnology’s pipeline and a robust financial position. ...

Why did Sana biotechnology stock soared after Phase 1 data?

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has de-risked its HIP platform. Read more here. ...

How much should you buy Sana (Sana) stock in 2026?

Analyst price targets range from $7 to $15, suggesting significant upside potential despite recent market challenges and a 71% stock decline over six months. Despite no revenue, Sana's strategic decisions have extended its cash runway into 2026, providing ample time to advance critical programs through development stages. ...

Will Sana's breakthrough data affect share prices?

As such, while I suspect the hype around Sana's breakthrough data will create share price targets that are artificially high, I also suspect that when the dust settles, the price will find a slightly lower trading range which may substantially undervalue this new business opportunity. ...

Will Sana stock correct downwards after a spike?

"After its initial spike, Sana stock is likely to correct downwards as the market prepares to wait years for more study data that could be used to support a formal approval submission," Ingham added. Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has de-risked its HIP platform. ...

Should you buy Sana (Sana)?

Like so many cell therapy developers, Sana initially proved terrible value for investor's money, but unlike so many of these companies, Sana may have made a momentous breakthrough with its T1D program. I will therefore assign its stock a “Buy” rating. However, I would advise retail investors to bide their time. ...